Novo Nordisk cuts forecasts as Ozempic and Wegovy sales hit by US copycat versions
Novo Nordisk has trimmed his income and earnings forecasts throughout the year for the first time since he launched his lush weight loss drug, since the unauthorized versions of his GLP-1 drugs eat in Laret. Itstés Itstés Itstés Itstés Itstés Itstés-itstes. Itstés The Danish drug manufacturer, which also markets Ozempic for diabetes, now expects sales […]
